Idera begins phase 1/2 oncology trial of HYB2055

By Jennifer Chiou

New York, Oct. 26 - Idera Pharmaceuticals, Inc. said it initiated a phase 1/2 clinical trial of HYB2055 with chemotherapy agents gemcitabine and carboplatin.

HYB2055 or IMOxine, Idera's lead toll-like receptor 9 agonist for cancer, is based on the company's Immune Modulatory Oligonucleotide (IMO) technology.

The trial is a two-phase, open-label dose escalation study of safety and efficacy.

"Our preclinical studies in animal tumor models demonstrated a significant added benefit from IMO treatment combined with several standard chemotherapies," Tim Sullivan, vice president of development programs, said in news release.

"As a result, we have initiated the trial and are seeking to enroll 12 to 18 refractory solid tumor patients in the phase 1 portion of the trial.

"We plan to use the phase 1 data for dose selection for the subsequent phase 2 portion of the trial in the treatment of naive non-small cell lung cancer patients."

Gemcitabine or Gemzar is Eli Lilly and Co.'s chemotherapy drug.

Idera, a biotechnology company focused on the development and commercialization of immune therapies based on Toll-like receptors that control immune response modulation, is based in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.